Faron Pharmaceuticals Oy FARN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FARN is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- GBX 127.50
- Day Range
- GBX 125.60–135.00
- 52-Week Range
- GBX 113.00–370.00
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 9.18 Bil
- Volume/Avg
- 1,513 / 32,111
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 34
- Website
- https://www.faron.com
Comparables
Valuation
|
Metric
|
FARN
|
02315
|
KURA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 3.82 | 3.68 |
Price/Sales | — | 4.17 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
FARN
|
02315
|
KURA
|
|---|---|---|---|
Quick Ratio | 0.47 | 1.02 | 12.02 |
Current Ratio | 0.59 | 1.30 | 12.26 |
Interest Coverage | −13.39 | −5.27 | −107.04 |
Quick Ratio
FARN
02315
KURA
Profitability
|
Metric
|
FARN
|
02315
|
KURA
|
|---|---|---|---|
Return on Assets (Normalized) | −249.08% | −13.53% | −27.08% |
Return on Equity (Normalized) | — | −37.28% | −29.62% |
Return on Invested Capital (Normalized) | −2,132.51% | −20.22% | −31.62% |
Return on Assets
FARN
02315
KURA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hnvlvwrp | Lyk | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mspxxcwyc | Tttxww | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nsxcfddnr | Dkyptg | $97.8 Bil | |
MRNA
| Moderna Inc | Lqyvxbgll | Jqls | $41.3 Bil | |
ARGX
| argenx SE ADR | Lnsqfgjgt | Ppwn | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Thtjfsykr | Sbpz | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Sctnmnhp | Blyhty | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Dglkcfdxw | Tzkvn | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kwdbrgbmd | Trxht | $12.5 Bil | |
INCY
| Incyte Corp | Qmbttdz | Dfxssyl | $11.6 Bil |